Solano SSR, Rodríguez CS, Maldonado MEP

Language: Spanish
References: 14
Page: 280-283
PDF size: 47.07 Kb.

ABSTRACT

Objective: To determine if the prolactin plasma levels differ in women with and without overactive bladder. Method: Cross-sectional design to compare plasma prolactin levels in women with and without overactive bladder. The diagnosis of overactive bladder was realized according to an autoapplicable questionnaire of eight questions «VH8». Results: We found statistically significant difference of means for the prolactin plasma levels, appearing plasma levels more elevated in patients with overactive bladder (77.16 versus 23.24 ng/dL). Conclusion: Women with overactive bladder present greater plasma levels of prolactin, probably by molecular biology mechanisms.

REFERENCES

1. Bernard TH, Dirk de R, Robert M et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21: 5-26.

2. Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder. J Pharmacol Sci 2010; 112: 128-134.

3. Solano SSR, Velázquez SMP, Rodríguez CS, Kunhardt RJ. Comparative study of overactive bladder prevalence in patients younger than 50 years with and without hyperprolactinemia. Ginecol Obstet Mex 2006; 74 (7): 345-348.

4. Pillai NP, Ramaswamy S, Gopalakrishnan V, Ghosh MN. Contractile effect of prolactin on guinea pig isolated ileum. Eur J Pharmacol 1981; 72 (1): 11-16.

5. Walters CA, Daly DC, Chapitis J, Kuslis ST, Prior JC, Kusmik WF, Riddick DH. Human myometrium: a new potential source of prolactin. Am J Obstet Gynecol 1983; 147 (6): 639-644.

6. Sauro MD, Zorn NE. Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. J Cell Physiol 1991; 148 (1): 133-138.

7. Sauro MD, Bing B, Zorn NE. Prolactin induces growth-related gene expression in rat aortic smooth muscle in vivo. Eur J Pharmacol 1992; 225 (4): 351-354.

8. Nowak RA, Rein MS, Heffner LJ, Friedman AJ, Tashjian AH Jr. Production of prolactin by smooth muscle cells cultured from human uterine fibroid tumors. J Clin Endocrinol Metab 1993; 76 (5): 1308-1313.

9. Nohara A, Ohmichi M, Koike K, Jikihara H, Kimura A, Masuhara K, Ikegami H, Inoue M, Miyake A, Murata Y. Prolactin stimulates mitogen-activated protein kinase in human leiomyoma. Biochem Biophys Res Commun 1997; 238 (2): 473-477.

10. Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells. Gynecol Obstet Invest 1999; 48 (2): 127-132.

11. Meli R, Gualillo O, Raso GM, Di Carlo R. Further evidence for the involvement of prolactin in the inflammatory response. Life Sci 1993; 53 (6): PL105-110.

12. Coyne KS, Margolis MK, Zyczynski T, Elinoff V, Roberts R. Validation of an OAB screener in a primary care patient population in the US. Poster presented at the Annual Meeting of the International Continence Society; August 23-27; Paris, France, 2004.

13. Hulley SB, Cummings SM, Browner WS. Diseño de investigaciones clínicas. Capítulo 6. 3ª edición. Barcelona, España: Lippincott Williams & Wilkins, 2008: 73-95.

14. Solano-Sánchez, SR. Prolactin plasma levels in women with and without idiopathic overactive bladder. Int Urogynecol J 2007; 18 (Suppl 1): S25-S105.